These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 19062158)

  • 1. Editorial comment on: external validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Blute ML
    Eur Urol; 2010 Jan; 57(1):110-1. PubMed ID: 19062158
    [No Abstract]   [Full Text] [Related]  

  • 2. Editorial comment on: External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Giannarini G; Autorino R
    Eur Urol; 2010 Jan; 57(1):109-10. PubMed ID: 19062156
    [No Abstract]   [Full Text] [Related]  

  • 3. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression levels of survivin protein independently predict a poor outcome for patients who undergo surgery for clear cell renal cell carcinoma.
    Parker AS; Kosari F; Lohse CM; Houston Thompson R; Kwon ED; Murphy L; Riehle DL; Blute ML; Leibovich BC; Vasmatzis G; Cheville JC
    Cancer; 2006 Jul; 107(1):37-45. PubMed ID: 16736510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The influence of pNx/pN0 grouping in a multivariate setting for outcome modeling in patients with clear cell renal cell carcinoma.
    Ward JF; Blute ML; Cheville JC; Lohse CM; Weaver AL; Zincke H
    J Urol; 2002 Jul; 168(1):56-60. PubMed ID: 12050492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma.
    Ficarra V; Novara G; Galfano A; Brunelli M; Cavalleri S; Martignoni G; Artibani W
    BJU Int; 2009 Jan; 103(2):165-70. PubMed ID: 18782313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of perinephric fat infiltration and tumor size in renal cell carcinoma.
    Yoo C; Song C; Hong JH; Kim CS; Ahn H
    J Urol; 2008 Aug; 180(2):486-91; discussion 491. PubMed ID: 18550101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of bilaterality, pathological features and surgical outcome in nonhereditary renal cell carcinoma.
    Blute ML; Itano NB; Cheville JC; Weaver AL; Lohse CM; Zincke H
    J Urol; 2003 Apr; 169(4):1276-81. PubMed ID: 12629342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. pT1 clear cell renal cell carcinoma: a study of the association between MIB-1 proliferative activity and pathologic features and cancer specific survival.
    Cheville JC; Zincke H; Lohse CM; Sebo TJ; Riehle D; Weaver AL; Blute ML
    Cancer; 2002 Apr; 94(8):2180-4. PubMed ID: 12001115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.
    Blute ML; Leibovich BC; Cheville JC; Lohse CM; Zincke H
    J Urol; 2004 Aug; 172(2):465-9. PubMed ID: 15247704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes following partial nephrectomy by tumor size.
    Crispen PL; Boorjian SA; Lohse CM; Sebo TS; Cheville JC; Blute ML; Leibovich BC
    J Urol; 2008 Nov; 180(5):1912-7. PubMed ID: 18801543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and external validation of a new outcome prediction model for patients with clear cell renal cell carcinoma treated with nephrectomy based on preoperative serum C-reactive protein and TNM classification: the TNM-C score.
    Iimura Y; Saito K; Fujii Y; Kumagai J; Kawakami S; Komai Y; Yonese J; Fukui I; Kihara K
    J Urol; 2009 Mar; 181(3):1004-12; discussion 1012. PubMed ID: 19150550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates.
    Crispen PL; Breau RH; Allmer C; Lohse CM; Cheville JC; Leibovich BC; Blute ML
    Eur Urol; 2011 Jan; 59(1):18-23. PubMed ID: 20933322
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Editorial comment.
    Campbell SC; Lane BR
    J Urol; 2010 Feb; 183(2):485; discussion 485. PubMed ID: 20006871
    [No Abstract]   [Full Text] [Related]  

  • 17. External validation of the Leibovich prognosis score for nonmetastatic clear cell renal cell carcinoma at a single European center applying routine pathology.
    Pichler M; Hutterer GC; Chromecki TF; Jesche J; Kampel-Kettner K; Rehak P; Pummer K; Zigeuner R
    J Urol; 2011 Nov; 186(5):1773-7. PubMed ID: 21944989
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymph node dissection is not obsolete in clinically node-negative renal cell carcinoma patients.
    Van Poppel H
    Eur Urol; 2011 Jan; 59(1):24-5. PubMed ID: 20943309
    [No Abstract]   [Full Text] [Related]  

  • 19. Editorial comment.
    Russo P
    Urology; 2010 Feb; 75(2):275-6; author reply 276. PubMed ID: 20152477
    [No Abstract]   [Full Text] [Related]  

  • 20. The use of simplified versions of the Fuhrman nuclear grading system in clinical practice requires the agreement of a multidisciplinary panel of experts.
    Ficarra V; Novara G; Martignoni G
    Eur Urol; 2009 Nov; 56(5):782-4; discussion 784-5. PubMed ID: 19660853
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.